Study Title: SCOT
Study Description: Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer
Study Design: Phase III, randomised controlled, two-arm multi-centre, non-inferiority study
Trial Status: Closed to recruitment, in follow-up
Chief Investigator: Dr Tim Iveson
Sponsor: Greater Glasgow & Clyde Health Board (GGCHB) and Glasgow University (GU)
Date Opened: 27th March 2008
Planned Closure Date: 29th Nov 2013
Target Recruitment: 9500 patients with fully resected high risk stage-II/stage-III colorectal cancer.
Open to New Sites: No
Contact Details: Clinical Trial Unit (CTU), Glasgow
Andrea Harkin/Karen Wilson
CRUK CTU, Glasgow
E-mail: [email protected]
Initiation Slides (Download)
SCOT Investigator Initiation Slides
SCOT Pharmacy Initiation Slides
Clinical Management Reference Documents
RSI Front Sheet
These are the current Summary of Product Characteristics (SmPCs):
Folinic Acid SmPC from 17 Oct 2012
Oxaliplatin SmPC from 10 Jul 2012
Capecitabine SmPC from 23 Jan 2014
5FU SmPC from 24 Aug 2011
For queries concerning Pharmacovigilance or the Reference Safety Information please contact:
The Pharmacovigilance Team email: [email protected] or
Telephone: 0141 211 0352/0203/3567/3968 or 0141 232 2068
Version of NCI Common Terminology Criteria for Adverse Events (CTCAE) being used for the study: 3.0
Click here to download the CTCAE
